E4NA Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EST
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€47.48M
Enterprise Value€66.46M
Total Cash (Recent Filing)€19.37M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,208,851,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA near-zero debt capital structure and a materially larger equity base reduce financial distress risk and interest burden, giving management durable flexibility to fund R&D or pursue partnerships without immediate refinancing pressure. This supports multi-quarter program execution and optionality.
Platform-focused Immunotherapy PipelineA platform approach centered on engineered immune cells and CAR technologies creates structural leverage: the same underlying technology can support multiple programs, improving scalable R&D efficiency and long-term value capture if clinical progress validates the modality.
Predictable Cash Burn Relative To LossesCash outflows that closely mirror accounting losses indicate cash burn is driven by core operating activity rather than hidden non-cash drains. That predictability aids multi-month liquidity planning and reduces risk of surprise cash shortfalls between financings.
Bears Say
Persistent Operating LossesSustained operating and free cash flow deficits indicate the business is not yet self-funding; over multiple quarters this erodes reserves and forces repeated external financing, diverting management attention and diluting shareholders while slowing long-term program development.
Revenue Volatility And Recent DeclineUnstable and shrinking revenue reduces ability to underwrite ongoing R&D and operations from internal cash flows. Revenue unpredictability complicates multi-cycle budgeting, increases reliance on capital markets, and weakens negotiating leverage with partners or licensors.
Negative Returns On EquityPersistent negative ROE signals the company is destroying shareholder capital; over months this can force dilutive equity raises or unfavorable financing, constrain strategic choices, and impair the firm's ability to attract long-term partner investment.
Arovella Therapeutics Limited News
E4NA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest stock price was €0.04 and its highest was €0.06 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is €47.48M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
Arovella Therapeutics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 37 days.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:E4NA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:E4NA Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €8.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.08%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Imugene
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―